CRME - 195854

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You?
    Simply Wall St.

    Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You?

    Measuring Cardiome Pharma Corp’s (TSX:COM) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • Zacks Small Cap Research

    CRME: Cipher to Get Canadian Assets

    Cardiome Pharma Corp. (CRME) issued a press release reporting 2017 full-year results on March 13, 2018, and filed its 2017 financial statements and management discussion & analysis on SEDAR three weeks later. During 2017, Cardiome advanced Xydalba in Europe with a commercial launch in several EU states.


    Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts Target Price, Financial Review

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...


    Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash

    Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...

  • Benzinga

    Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

    CARDIOME PHARMA CORP (NASDAQ: CRME ) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million.  The Analyst Canaccord Genuity's ...

  • Zacks Small Cap Research

    CRME: Cardiome’s 2017 Full Year Results

    Cardiome was involved in substantial activity during the prior twelve months, beginning with the recognition of sales for Zevtera/Mabelio, the launch of Xydalba in several new geographies, and the expansion of the reach of Brinavess.  China’s regulatory authority granted Aggrastat an additional indication and SteadyMed is on track for its new drug application (NDA) for Trevyent.  As we began 2018, Esmocard posted record months in both January and February. In September, Cardiome entered into an agreement with Basilea to commercialize ceftobiprole (Zevtera/Mabelio) in 34 European countries and Israel.  Following the transaction, revenues were recognized on Cardiome’s income statement and beginning January 1st, 2018 all of Basilea’s sales representatives were added to Cardiome’s sales force.  Management commentary noted that they were able to achieve historical peak sales levels of the drug in January and surpass that in February, suggesting that better days are still ahead.


    Cardiome Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Cardiome Pharma Corp. (NASDAQ: CRME ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018 at 4:30 PM Eastern Time. ...

  • Cardiome Pharma Corp (TSE:COM): Is Breakeven Near?
    Simply Wall St.

    Cardiome Pharma Corp (TSE:COM): Is Breakeven Near?

    Cardiome Pharma Corp’s (TSX:COM): Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company’sRead More...

  • Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?
    Simply Wall St.

    Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?

    Investors are always looking for growth in small-cap stocks like Cardiome Pharma Corp (TSX:COM), with a market cap of CA$63.04M. However, an important fact which most ignore is: how financiallyRead More...

  • Best TSX Growth Stocks
    Simply Wall St.

    Best TSX Growth Stocks

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...